艾迪药业：抗HIV领域在研1类新药ACC017片III期临床试验首例受试者成功入组

Core Viewpoint - The company announced that its self-developed HIV drug ACC017 is currently undergoing Phase III clinical trials, with the first subject successfully enrolled on November 7, 2025 [1] Group 1: Drug Development - ACC017 is a novel chemical structure integrase strand transfer inhibitor (INSTI) targeting HIV, developed independently by the company [1] - The drug works by inhibiting the activity of the HIV integrase, effectively blocking the integration of the HIV genome into the host's DNA [1] - The clinical application of ACC017 is intended for the treatment of HIV infections [1]